T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight. In report published in Nature Medicine,

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.

Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do not inform patients of the risks associated with these medicines, according to a research letter published on Friday.

A recent study reveals many websites selling compounded versions of weight-loss drugs do not inform users of risks, often misleading users about FDA approval. Researchers identified over 70 websites with vague safety disclosures.

Popular GLP-1 medications for weight loss and diabetes may have unexpected benefits for reducing risks for conditions such as substance abuse, psychosis, infections and even dementia. But these drugs also come with risks that shouldn't be overlooked,

Obesity expert Dr. Naomi Parrella of Rush University joins Marie Saavedra to talk about the new study and the impact for patients.

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have rapidly emerged as game-changers in treating diabetes, heart disease, and obesity. Commonly marketed under brand names like Ozempic and Wegovy,